Safety of Phenylephrine in Antihypotensive Treatment during Spinal Anesthesia for Cesarean Sectio

Not Applicable

Completed

• Conditions: Phenylephrine- induced bradycardia in treatment of spinal anesthesia- induced hypotension in parturients undergoing cesarean section.; Bradycardia; Phenylephrine; Hypotension; Spinal anesthesia; Cesarean section

• Registration Number: TCTR20141017001
• Lead Sponsor: Graduate school Chulalongkorn university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-10-17
• Study Completion: 2015-01-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 610

Inclusion Criteria

-ASA I,II
-Age greater than or equal 18 years old.
-Singleton baby.
-Gestational age greater than or equal to 37 weeks

Exclusion Criteria

Chronic hypertension, gestational hypertension or preeclampsia.
- Cardiovascular disease (ischemic heart disease, valvular heart disease, cardiac defect) or cerebrovascular disease (stroke, cerebral aneurysm, cerebral arteriovenous malformation)
- Complicated obstetrics (abruptio placenta, placenta previa)
- Known fetal abnormalities (intrauterine growth retardation(IUGR), fetal cardiac disease)
- History use of monoamine oxidase inhibitor(MAOI).
- History use of other drugs that prolonged heart conduction(PR or QT interval)
- Contraindications to spinal anesthesia (coagulopathy, intracranial space occupying lesion or patient refusal)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidences of phenylephrine-induced bradycardia in treatment of spinal anesthesia-induced hypotensio End of study Percentage

Secondary Outcome Measures

Name	Time	Method
Association of pretherapeutic heart rate and phenylephrine-induced bradycardia End of study Relative risk,The optimal cut-point of heart rate that safe for using phenylephrine End of study Multivariable logistic regression,The incidences of severe adverse events End of study Percentage